Conferences - Results from #200

AUA 2023: What is the "Best" Diversion: Conduit or Neobladder? May 1, 2023

AUA 2023: Optimal TURBT: Do Skilled Urologists Really Need PDD? May 1, 2023

AUA 2023: Pathology or 'Markers': What is More Important? May 1, 2023

AUA 2023: Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer (AFT-19) May 1, 2023

AUA 2023: Results From the Extended Follow-up in Patients With Muscle-Invasive Bladder Cancer in the Checkmate 274 Trial May 1, 2023

AUA 2023: Artificial Intelligence-Enabled Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy May 1, 2023

AUA 2023: Role of Adjuvant Immunotherapy for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection May 1, 2023

AUA 2023: A Single Centre Prospective Randomized Controlled Study to Assess Outcomes and Complications of Conventional Stent Placement Versus No Stent Placement after Ureteroscopy for Distal Ureteric Calculus of Size 1 cms May 1, 2023

AUA 2023: Optimal Management of cN+ Muscle Invasive Bladder Cancer May 1, 2023

AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges May 1, 2023

AUA 2023: Perioperative Outcomes of Radical Cystectomy Following Neoadjuvant Gemcitabine, Cisplatin and Atezolizumab May 1, 2023

AUA 2023: Second Update: Is Combination Therapy the New Standard of Care for Metastatic Castrate Resistant Prostate Cancer Patients? May 1, 2023

AUA 2023: Prostate Cancer Guidelines — Where I See Progress and Help with My Practice May 1, 2023

AUA 2023: First Update: Managing our Metastatic Hormone Sensitive Prostate Cancer Patients: Are We There Yet? May 1, 2023

AUA 2023: The Effects of Sequential Mitomycin and BCG Treatment Versus BCG Monotherapy in Patients With High-risk Non-muscle Invasive Bladder Cancer: MITO-BCG April 30, 2023

AUA 2023: First Results from SunRISe-1 in Patients with BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 in Combination With Cetrelimab, TAR-200, or Cetrelimab Alone April 30, 2023

AUA 2023: Biochemical Recurrence of Localized Prostate Cancer Originating From the Transition Versus Peripheral Zone: a Systematic Review and Meta-Analysis April 30, 2023

AUA 2023: New Guidelines for Sexual Health Care with Prostate Cancer April 30, 2023

AUA 2023: Debate: Renaming Gleason 6 Prostate Cancer April 30, 2023

AUA 2023: Associations Between Prostate MRI and Genomic Testing and Treatment Intensification Among Patients with Localized Prostate Cancer April 30, 2023

Page 11 of 522